Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Bonesupport Holding AB (publ) (BONEX) Ordinary Shares

Sell:42.75 SEK Buy:43.05 SEK Change: 1.70 SEK (4.11%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:42.75 SEK
Buy:43.05 SEK
Change: 1.70 SEK (4.11%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Sell:42.75 SEK
Buy:43.05 SEK
Change: 1.70 SEK (4.11%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.

Contact details

Scheelevagen 19
223 70
+46 (46) 2865370

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
2.66 billion SEK
Shares in issue:
65.43 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Lennart Johansson
    Independent Chairman of the Board
  • Emil Billback
    Chief Executive Officer
  • Hakan Johansson
    Chief Financial Officer
  • Fergus MacLeod
    General Manager, Executive Vice President - Commercial Operations EUROW
  • Michael Roth
    Executive Vice President - Commercial Operations North America, General Manager
  • Annelie Vikner
    Executive Vice President Marketing & Communications
  • Michael Diefenbeck
    Executive Vice President Research & Development, Medical & Clinical Affairs, Chief Medical Officer
  • Kristina Ingvar
    Executive Vice President - Quality Management & Regulatory Affairs
  • Johan Olsson
    Executive Vice President- Manufacturing and Supply
  • Helena Brandt
    Head of Human Resources

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.